Loading clinical trials...
Loading clinical trials...
This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.
Patients who received previous adjuvant or salvage radiotherapy to the prostate bed \> Isolated prostate bed recurrence based on PSMA PET, biopsy-proven, and MR visible \> Baseline: QoLs questionnaires, PSA, pelvic magnetic resonance imaging (MRI) scan for RT planning \> Two fractions of 13 Gy each delivered over 7-21 days. GTV(HDR) delineation (based on MRI-guided and PSMA PET, biopsy data as applicable) \> Follow-Up after treatment 60 months: PSA, CTCAE v5.0, MRI pelvis +/- PSMA-PET scan (optional at 24 months)
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Start Date
August 8, 2024
Primary Completion Date
August 8, 2026
Completion Date
March 1, 2031
Last Updated
February 10, 2025
20
ESTIMATED participants
High Dose Rate Brachytherapy
RADIATION
Lead Sponsor
University Health Network, Toronto
NCT05691465
NCT06842498
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04550494